广州安必平医药科技股份有限公司2025年年度业绩预亏公告

Core Viewpoint - Guangzhou Anbiping Pharmaceutical Technology Co., Ltd. is expected to report a significant net loss for the fiscal year 2025, with projections indicating a loss between 52 million to 42 million yuan, representing a year-on-year decrease of 344.23% to 297.26% compared to the previous year [3]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [2]. - The expected net profit attributable to the parent company is projected to be between -52 million to -42 million yuan, a decrease of 73.29 million to 63.29 million yuan compared to the previous year [3]. - The expected net profit attributable to the parent company after deducting non-recurring gains and losses is projected to be between -72 million to -62 million yuan, a decrease of 86.25 million to 76.25 million yuan compared to the previous year [3]. Group 2: Previous Year Performance - In the previous year, the total profit was 9.43 million yuan, with a net profit attributable to the parent company of 21.29 million yuan [5]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 14.25 million yuan [5]. - The earnings per share for the previous year was 0.23 yuan [6]. Group 3: Reasons for Performance Change - The company's operating income has declined, primarily due to the implementation of national centralized procurement policies, which significantly reduced the selling price of HPV product lines, leading to a revenue decrease of approximately 46.5 million yuan [7]. - The gross profit margin for the HPV product line has also been under pressure, resulting in a gross profit decrease of about 46 million yuan [7]. - The company is actively optimizing its business structure and focusing on expanding its main business revenue while reducing the scale of agency product business [7]. - To build long-term competitive advantages, the company is increasing its investment in product research and innovation, particularly in the fields of pathological intelligence and tumor companion diagnostics, which has led to an increase in operating costs [7]. - The company has made provisions for asset impairment in accordance with accounting standards and policies [7]. Group 4: Non-Operating Gains and Losses - The increase in non-recurring gains and losses is mainly due to increased investment income from associated companies [9].